WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 7, 372-388. Review Article ISSN 2277–7105

A REVIEW ON PSORIASIS: A LIFE THREATNING DISEASE

Dhakrao Shubham Vijay*, Jagadale Shrikrushna Rajendra and Prof. Sangle S. J.

(Department of Pharmaceutics) Matoshri College of Pharmacy, Eklahare, Nashik.

Article Received on
13 Feb. 2024,

Revised on 04 March 2024,
Accepted on 25 March 2024

DOI: 10.20959/wjpr20247-31858

***Corresponding Author**
Dhakrao Shubham Vijay
(Department of Pharmaceutics) Matoshri College of Pharmacy, Eklahare, Nashik.

ABSTRACT

The psoriasis is habitual skin complaint that causes the symptoms like abnormal skin cell growth, red circles, patches etc. It's also known as erythematous pustules with argentine scales. The two types of study are used for the pathologic changes on the cellular situations. The utmost of cases comes in the age observed age in between the periods of 15 and 30. In the study, the reason for psoriasis complaint is due to a inheritable vulnerability as well as an environmental response. The estimated periodic cost$32.5 billion for treating psoriasis in United States. There are number of available retailed treatment for psoriasis in different phrasings like topical and systemic phrasings. But, topical expression was considered as stylish potent system as compared with systemic one due to the lower adverse goods and targeted styles. Herbal, homeopathic approaches are also helps to control the growth of psoriasis with low side goods as compared with topical allopathic medicines.

KEYWORDS: Autoimmune, Psoriasis, Treatment, Habitual, Pathology.

INTRODUCTION

Psoriasis is an autoimmune habitual seditious skin complaint. It's characterized by erythematous pustules or pillars with argentine scales. principally, this complaint causes the circles or patches of abnormal skin cell generation. It's observed as increased in proliferation of epidermal subcaste related to defaulted vulnerable system function. The observed psoriasis skin patches are generally red in the color, lack of humidity or dry skin, itching on inflamed skin portion. The psoriasis initiated from small, localized patches to content of complete body. The first case of psoriasis was described in Ancient Rome by Cornelius Celsus. The British dermatologist Thomas Bateman described a link between psoriasis and arthritic symptoms in1813.2 The word psoriasis deduced from the Greek word" psora" stands for"

itch". For detailed studies, psoriasis distributed in different classes as shrine psoriasis, invasive psoriasis, psoriatic arthritis, crown psoriasis, nail psoriasis and numerous further. In International Federation of Psoriasis Associations (IFPA), around 3 of the world population has some symptoms of psoriasis (125 million people). In India, further than 10 million cases per time observed. Due to the adding number of cases, it comes under common order. thus, alleviation comes in scientists that we need to do further sweats on the psoriasis treatment. Etiology of this habitual condition isn't clear. Stress is the most common etiological factor and cases with habitual diseases like Crohn's complaint are more likely to suffer from psoriasis.[6,7] medicines that appear to have a strong unproductive relationship to psoriasis are beta- blockers, lithium, synthetic antimalarials, nonsteroidalanti-inflammatory medicines (NSAIDs), and tetracyclines.[8] Cases with severe form of this complaint have an increased threat of cardiac co- morbidities.[9] In this review, we compactly bandy about the immunopathogenesis followed by the being curatives for the treatment of psoriasis. In addition, the review focuses on the newer target grounded curatives. The biologics which are presently approved for psoriasis by FDA and many which are still in channel to be approved, have also been reviewed. Psoriasis is incompletely due to inheritable and incompletely due to environmental factors.[4] Psoriasis can be distributed as mild, moderate and severe. Mild psoriasis leads to conformation of rashes and when it becomes moderate the skin turns scaled. In severe conditions, the red patches may be present on skin face and come itchy. This affects a person's professional and social life. The normal medium of body is to form new skin cells every month to replace the skin which is exfoliate off. But, in psoriasis the new skin cells grow fleetly within days rather than weeks. This leads to accumulation of dead skin on the skin face performing in thick patches of red, dry and itchy skin. Psoriasis is a skin complaint that causes scaling and inflammation (pain, swelling, heat, and greenishness) causing patches of thick, red skin with argentine scales. The vulnerable system plays a crucial part in psoriasis. The vulnerable system makes white blood cells that cover the body from infection. In psoriasis, the T cells (a type of white blood cells) abnormally spark inflammation in the skin. They also beget skin cells to grow faster than normal and to pile up in raised patches on the external face of the skin.[1] typically, skin cells that are formed in the deepest layers of mortal skin make their way to the face. This process is called cell development. They develop, are sloughed off the body's face, and are replaced with new skin cells from below. This cycle takesapproximately a month. In people with psoriasis; still, the vulnerable system activates a briskly- than-normal skin cell cycle. The body doesn't exfoliate these redundant skin cells, leading to the cells pile up on the face of the skin and lesions form. Psoriatic pillars

pose the problem of poor penetration of medicines. Preferable characteristics of topical delivery of medicines include low molecular mass, acceptable solubility in oil painting and water and a high partition measure. Emulgel system meets all the criteria laid down for topical drug delivery. The lack of possible cure and associated disadvantages in allopathic medicines has led to an extensive research in natural products with anti-psoriatic activity. The literature survey reveals that although extensive work has been reported on the treatment of psoriasis

Causes: The cause of psoriasis is not fully understood, but there are several factors responsible which include genetics, environmental factors and the immune system. Genetics: It plays a major role in the development of this disease. Approximately 10% of the general population have genes which are predisposed to psoriasis; But out of 10% only 1-3% of the populations develops the disease. Family with history of psoriasis have higher chance to develop this disease. Identical twin studies suggested a 70% chance of a twin developing psoriasis, if the other twin has the disease. The chance of developing disease is 20% in case of non-identical twin. These studies suggests both genetic and environmental factors are responsible in developing psoriasis.

Environmental factors: Certain environmental factors trigger the psoriasis gene to become active. Some of the factors are[14]:

- Infections, such as streptococcal throat or skin infections
- Injury to the skin, such as a cut or scrape, a severe sunburn
- Stress
- Cold weather
- Smoking
- Obesity
- Heavy alcohol consumption
- Folate and vitamin B12 deficiency
- Certain medications like lithium, which is prescribed for bipolar disorder; high blood pressure medications such as beta blockers and antimalarial drugs.
- Co-morbidities of psoriasis: Psoriasis is associated with high morbidity and great level of psychological stress. The co-morbidities of psoriasis are:
- Psoriasis arthritis
- Cardiovascular disease and metabolic syndrome

- Crohn's disease
- Cancer.

Immune system: In a normal healthy individual, T-cells which is a part of White blood cells (WBC's), protect the body against infection by identifying and destroying foreign material. But, in psoriasis, T-cells are over-activated. Over-activation of T cells trigger other immune responses like dilation of blood vessels in the skin around the plaques, stimulation of inflammatory chemical signal (cytokines) such as the tumor necrosis factor- α,interleukin-1 β,interleukin-6,interleukin-36 and interleukin-22.[15,16] These secreted inflammatory signals stimulate T-cells proliferation which causes an ongoing cycle in which new skin cells move to the outermost layer of skin too quickly, in days rather than months and weeks leading to formation of dead skin which is built up in thick, scaly patches on the skin's surface.[13]

Pathophysiology

Psoriasis is immune mediated disease which is mostly caused by faulty signal of own immune system. It is believed that psoriasis develops when skin cells multiply at a faster rate as compared to normal skin cells growth rate. Normally, the cells mature and shed from the skin's surface every 28 to 30 days.[17] In case of psoriasis, the skin cells mature in 3 to 6 days and move to epidermis. Instead of being shed, the skin cells accumulate on epidermis and cause visible lesions. There are mainly two hypotheses involved in the development of the disease. The first hypothesis states that psoriasis is primarily a disorder of excessive growth and reproduction of skin cells. The second hypothesis states, that the disease is an immune mediated disorder in which the excessive reproduction of skin cells is secondary to factors produced by the immune system.[18,19]

Antigen-presenting cells in the skin, such as Langerhans cells, are believed to migrate from the skin to regional lymph nodes, where they interact with T cells. Co-stimulatory signals are factor lead to the inflammation, cell mediated immune responses, and epidermal hyper-proliferation observed in persons initiated via the interaction of adhesion molecules on the antigen-presenting cells, such as lymphocyte function-associated antigen (LFA)-3 and intercellular adhesion molecule, with their respective receptors CD2 and LFA-1 on T cells. These T cells are released into the circulation and traffic back into the skin. Reactivation of T cells in the dermis and epidermis and the local effects of cytokines such as tumor necrosis factor lead to the inflammation, cell mediated immune responses, and epidermal hyper-proliferation observed in persons with psoriasis. Current research suggest that the

inflammation involved in the disease is because of immune system and most likely initiated and maintained by T cells in the dermis.

The excessive growth of skin epidermal cells is known as the psoriasis skin disorder (T lymphocyte-mediated autoimmune disease). There are study of pathologic change on the cellular levels (both in epidermis and dermis). The two main procedures occur in development of psoriasis sis. In the first process, is characterized by uncontrolled growth as well as reproduction of the skin cells. Whereas, the second process is characterized by disorder of immune-mediated in which the excessive reproduction of skin cells occurs[5,6] It is diminished leads to an over-activation of CD8-T-cells, this will be responsible to development of psoriasis to a HIV patients. In the different complications of psoriasis include the psoriatic arthritis, eye conditions, heart problems, obesity and diabetes, bad body temperature regulation, etc. In complication of alcohols, the drinking alcohol is a factor. Other complication includes the irritation from the heat and sweat. Whereas, the secondary fungal infections particularly Candida (thrush), by the scratching of skin as well as rubbing, difficulties with sexual functions are considered as few complications when the excessive usage of topically applied creams of steroids.

Pharmacology of Psoriasis: In psoriasis, there is abnormally excessive and rapid growth of the epidermal layer and abnormal production of skin cells just like during wound repair and skin cells overabundance leads the pathological events in psoriasis. Replacement of skin cells done in every 3-5 days interval in psoriasis condition as compare with usually normal 28-30 days process. The main causes of these kinds of changes are from the premature maturation of keratinocytes induced by an inflammatory cascade in the dermis involving dendritic. Cells, macrophages, and T- cells (three subtypes of white blood cells). These immune cells move from the dermis to the epidermis and secrete inflammatory chemical signals (cytokines) such as interleukin-36γ, tumor necrosis factor-α, interleukin- 1β, interleukin-6 and interleukin-22. These inflammatory signals are responsible to stimulate keratinocytesto proliferate. Gene mutations of proteins involved in the skin's ability to function as a barrier have been identified as markers of susceptibility for the development of psoriasis.8,9 DNA released from dying cells acts as an inflammatory stimulus in psoriasis and stimulates the receptors on certain dendritic cells, which in turn produce the cytokine interferon-α. In response to these chemical messages from dendritic cells and T cells, keratinocytes also secrete cytokines such as interleukin-1, interleukin-6 and tumor necrosis factor-α which signal downstream

inflammatory cells to arrive and stimulate additional inflammation. Dendritic cells bridge the innate immune system and adaptive immune system. They are increased in psoriatic lesions and induce the proliferation of T cells and type 1 helper T cells (Th1). Targeted immunotherapy and ultraviolet

A (PUVA) therapy can reduce the number of dendritic cells.



Diagnosis: The diagnosis of the psoriasis is usually based on the appearance of the skin. There are no special blood tests or diagnostic procedures for psoriasis. Sometimes a skin biopsy or scraping may be needed to rule out other disorders and to confirm diagnosis. Skin from a biopsy will show clubbed pegs if positive for psoriasis. Another sign of psoriasis is that when the plaques are scraped, one can see pinpoint bleeding from the skin below. Diagnosis of psoriasis is made easily by clinical examination. Usually there are no tests are required to diagnose psoriasis, but to rule out other complications blood tests, urine test and imaging studies are often performed

TOPICAL TREATMENTS

Psoriasis is a lifelong condition. There is currently no cure but various treatments can help to control the symptoms. There are three types of treatments viz topical treatments, light therapy (phototherapy) and oral medication. Topical treatments like (creams, lotions, gels, ointments, moisturizers applied to the skin) are usually the first line treatment and they help to reduce the accelerated production of skin cells and inflammation.

Agents used in Psoriasis treatment

Topical Corticosteroids

They are used as first line agents and also in combination with other topical agents.[22,23] They slow down cells turnover by suppressing the immune system, which reduces inflammation and relieves associated itching. They also have vasoconstriction properties. Corticosteroids are classified based on Potency according to their vaso-constrictive properties.[22,24,25] According to USA there are seven potencies groups viz Less Potent (least potent), Potent, Upper mild strength, Mild strength, Lower mild strength, Mild, Very high potency (Super-potent). The UK considers four classes: mild (class IV), moderately potent (class III), potent (class II), and very potent (class I).[22,24,26,27]

Lower-potency corticosteroids are particularly recommended for application on the face, groin, axillary areas, and in infants and children, whereas mid and higher-potency corticosteroids are commonly used for other areas in adults. Super-potent corticosteroids are mainly used for stubborn, cutaneous plaques or lesions on the palms, soles, and/or scalp.[24,28] Side-effects include hypopigmentation, striae, skin atrophy and tachyphylaxis.[29]

Coal Tar

The benefits of Coal tar have been known for many years. The use of coal tar has declined due to the availability of other topical agents. It is used to treat mild, moderate and severe Psoriasis. It relieves itching, swelling. It also inhibits enzymes that contribute the pathogenesis of psoriasis. A coal tar solution of between 1-5% has been proven as a safe product. Side-effects include its strong smell, irritation, staining of clothes and potential for causing photosensitivity.[30,31]

Topical vitamin D3 analogs

Calcipotriol (Calcipotriene), calcitriol and tacalcitol are analogues of vitamin D3.Calcitriolnaturally occurring active form of vitamin D3.These agents blocks epidermal proliferation, enhances maturity of cells, and has anti-inflammatory effects. It is no more effective than the moderately potent topical steroids, but combination of calcipotriol with topical steroids is more effective than either agent alone. Calcipotriol is very expensive. Vitamin-D helps to regulate calcium and phosphorus in the body and can also be produced by the skin when exposed to UVB light. Side-effects include Skin irritation- 20% of patients particularly on the face and in skin fold.[32,33]

Dithranol

It is also called as Anthralin. This is used for treating thick plaques of psoriasis. This is a traditional medicine chrysarobin and has been in use for a century. It is used in the concentration of 0.1-1%. Side- effects include skin irritation and brownish discoloration of skin, it may stain cloths. Therefore, it is known as short contact therapy. Contact with the face, eyes or mucous membrane must be avoid.[30,34]

Tazarotene

Tazarotene is a synthetic retinoid with properties similar to that of Vitamin-A. It may be used as a single agent or in combination with a corticosteriod, calcipotriol or phototherapy. Common side effect is irritation, which can be minimized by applying a thin layer of medication only to the patches and avoiding the uninvolved surrounding skin. It should not be used on the genitals or in the skin folds. It is contraindicated in pregnancy.[35]

Tacrolimus

It has immunosuppressant activity and used to treat both Psoriasis and Atopic dermatitis. It may be beneficial over sensitive areas like the face, genitelia and intertriginousareas.[36,37]

Salicylic acid: It is a keratolytic agent. It is used to remove scales that appear on skin. It is used in combination with other topical agents, it takes off the upper layer of skin allowing the additional agent to penetrate more effectively into the deeper layers. It is used in a concentration of 2-10%, it is usually combined with coal tar, steroids and dithranol. Side-effects include Moderate or severe skin irritation, flushing, unusually warm skin and reddening of skin.[38]

Available Marketed Formulations to the Treatment of Psoriasis

a) Topical Agents: In case of topical agents, topical corticosteroid preparations are playing the important role when applied continuously for 8-10 weeks. The different classes of retinoids and coal tar were observed as the limited therapeutic benefits. The different kinds of Vitamin D analogues were observed to be higher effective to placebo effects.[12]

b) Systemic Agents: The systemic medications used in case of when other treatments like topical agents, phototherapy resists by diseases. The oral formulations and injections are comes under the class of systemic agents. One thing is important in case of systemic treatment is on regular basis test of liver functions and blood test also.[12] The frequently used

treatment for psoriasis is non-biologic systemic treatments (methotrexate, hydroxycarbamide, fumarates such as dimethyl fumarate and retinoids) (Table 1). Whereas, in case of biologics, these are the proteins drug manufactured, they have the properties of interrupt the processes of immune that will involve in psoriasis. These kinds of medications are known to be well tolerated. Whereas their immunosuppressive actions will leads to increase in the small risk for infection.

c) UV Phototherapy: The sunlight has been used from a long time for treatment of psoriasis. The wavelength ranges from 311–313 nm having the high effects therefore the lamp have been developed for this kind of therapy. The time of exposure should be specific to avoid over exposure that will leads to the skin burn. The UV lamps should be attached with a timer with help of which the overtime exposure to the UV light. The skin type is an important factor to adjust the time of exposure to UV light.[14] The risk factor in UV light therapies are tanning beds (no exception), specifically in the link between UV light will leads to increased chance of skin cancer as well as the increased risks of melanoma, new younger patients particularly the age of 35, having the higher in risk from melanoma from treatment of UV light. Psoralen and ultraviolet A phototherapy (PUVA) combines the oral or topical administration of psoralen with exposure to ultraviolet (UV) light. The mode of action of PUVA is well studied, but probably having involves the activation of psoralen by UVA light that will inhibit the abnormal production of the rapid cells in the skin (psoriatic). The multiple mode of mechanisms that are associated with PUVA.[15]

d) Diet: The first risk factor is drinking alcohol because white blood cells (WBC) and T-cells will release to dilation of blood vessels. The different kind of cold drinks, processed foods also affects the health of skin. The omega-3-fatty acids help to control inflammation as well as boost the immune system. By drinking sufficient amount of 2-3 liters water for good moisturized skin.[14,16]

e) Natural Remedies for the Treatment of Psoriasis

The traditional medicines give a great positive promise as an easily available source of positive therapy for different kinds of diseases of skin specifically in the tropical developing countries including India has shown in table 1.

f) Homeopathic Approaches in Psoriasis: The approaches through allopathic medication have aim on the causative factors and diseases. In the homeopathy treatment, indications of

the patient give the positive results for one patient to compare to another patient. As well as in other systems, the medicines are usually selected to inhibit the process of epidermis cells proliferation. Homoeopathy medication is one of the safe, secure and gives better results by enhancing the energy to psoriasis without any kind of observed side effects.[17,18] Some of the marketed formulations available for the treatment of psoriasis are Ars alb, Arg Nit, Baryta Mur, Corralium, Crabapple, Hudrocytole, Kali ars, Kali Brom, Lycopodium, Nat pulp, Phosphorus, Psoralea, Psorinum, Pulsatilla, Urtica urens, and many more.

NOVEL DRUG DELIVERY SYSTEMS FOR PSORIASIS

Conventional therapy has many limitations which include poor drug solubility, insufficient drug concentration due to poor absorption, low permeability, rapid metabolism and elimination, drug distribution to other tissues combined with high drug toxicity and short half-life.[39] Novel drug delivery systems (NDDS) is a promising strategy to overcome these side-effects and offer many advantages which include increased safety and efficacy, drug targeting specificity and lowering of systemic drug toxicity.[40,41] Stratum corneum (SC) is the main barrier in percutaneous absorption of topically applied drugs. Small and relatively narrow size distribution with novel carriers permit site specific delivery to the skin with improved drug solublization of hydrophobic drugs and better bioavailability.[42] Nanocarriers play an important role in drug delivery to the target site for control and prevention of the disease.[43] Such carriers have become the first choice to deliver anti-psoriatic drugs, due to their various characteristics such as:

- Excellent biocompatibility and biodegradability[44]
- Non-toxic and degradable nature[45]
- Easily eliminated from the body[44]
- Stable at physiological and atmospheric conditions[46]
- Longer duration of action[45]
- Sustained and controlled drug release to the target site.[47]

Novel Formulations

Liposomes

Liposomes are spherical microscopic vesicles consisting of phospholipid bilayers which enclose aqueous compartments or active drug. Drug molecules can either be encapsulated in the aqueous compartment or into the lipid bilayer; the exact location of a drug in the liposome

will depend upon its physicochemical characteristics and the composition of the lipids.[48] Components of liposomes are phospholipids, cholesterol, and long chain fatty acids.[49]

Advantages include biocompatible, biodegradable, non-toxic, non-immunogenic and have the ability to protect the encapsulated drug from the external environment.[50]

Niosomes

Niosomes are non-ionic surfactant vesicles containing non-ionic surfactants instead of phospholipids in the bilayer of liposomes. They are microscopic lamellar structures obtained on hydration of non-ionic surfactant, cholesterol, and other lipids.[54] It is capable of entrapping both hydrophobic and hydrophilic drugs. This novel carrier is used in the formulation of various drugs to enhance the penetration and also to sustain the release of the drug.[55,56]

Advantages include enhanced skin penetration, greater stability, osmotically active and stable, low cost.[57]

Lakshmi PK, et al 2007 studied the preparation of niosomal Methotrexate (MTX) in chitosan gel by thin film hydration method. It was concluded that the niosomal MTX gel when compared with placebo and marketed MTX gel, results shows niosomal MTX gel is more effective.[58]

Ethosomes

Ethosomes are mainly composed of phospholipids, ethanol or other volatile alcohols at relatively high concentrations (up to 50%) and water[59] containing fluidized phospholipid bilayers generating vesicles with a soft structure. An additional essential role of ethanol present in the system is fluidization and disturbance of stratum corneum and to enable penetration into deeper layers of skin. This novel carrier system has drug delivery into deeper layers of skin or into the systemic circulation.[60]

Ethosomal formulations can be non-invasive, non-toxic, high permeability, promote patient compliance.

Dubey V, et al 2007 studied the preparation of Methotrexate (MTX) loaded ethosomes by mechanical dispersion method. It was concluded that MTX loaded ethosomes have drug targeting at epidermal and dermal sites and modern approach in the treatment of psoriasis.[61]

Microemulsions

Microemulsions are thermodynamically stable isotropic systems wherein two immiscible liquids (water and oil) are mixed to form a single phase by means of an appropriate surfactant or its mixture. Short to medium chain alcohols are generally considered as co-surfactants in the microemulsion system. The presence of surfactant and co-surfactant in the system makes the interfacial tension very low. They can solublise both hydrophilic and hydrophobic drugs.[62]

Advantages include ease of preparation, long-term stability, high solubilization capacity for hydrophilic and lipophilic drugs, and improved drug delivery.[63] Niosomes are non-ionic surfactant vesicles containing non-ionic surfactants instead of phospholipids in the bilayer of liposomes. They are microscopic lamellar structures obtained on hydration of non-ionic surfactant, cholesterol, and other lipids.[54] It is capable of entrapping both hydrophobic and hydrophilic drugs. This novel carrier is used in the formulation of various drugs to enhance the penetration and also to sustain the release of the drug.[55,56]

Advantages include enhanced skin penetration, greater stability, osmotically active and stable, low cost.[57]

Lakshmi PK, et al 2007 studied the preparation of niosomal Methotrexate (MTX) in chitosan gel by thin film hydration method. It was concluded that the niosomal MTX gel when compared with placebo and marketed MTX gel, results shows niosomal MTX gel is more effective.[58]

Solid lipid nanoparticles

Solid Lipid Nanoparticle (SLN's) are nanosized carrier systems in which solid particles consisting of a lipid matrix are stabilized by surfactants in an aqueous phase. The SLN structure is composed of solid core, which may contain triglycerides, glyceride mixtures, or waxes that are solid at both room temperature and human body temperature. Incorporation of both lipophilic and hydrophilic drugs into SLN's are possible.

SLN's can be biocompatible, biodegradable, have controlled drug delivery, specific drug targeting[66], have negligible skin irritation, protect active compounds and imparts sustained drug release to avoid systemic absorption.[67]

Madan JR, et al 2014 studied the preparation of Mometasone Furoate (MF) loaded SLN's gel by Solvent injection method. It was concluded that greater skin deposition and slow drug release and MF loaded SLN's gel could be a new, cost-effective and commercially viable alternative to the marketed product.[68]

CONCLUSION

The psoriasis is an bus-vulnerable complaint and its treatment is grounded on the treatment of symptoms and causes. The retailed expression for the treatment of this complaint is topical corticosteroids, herbal phrasings, systemic corticosteroids and other derivations in the form of tablets, injections etc. In the inheritable position study, scientists are linked that the different kinds of events causes the activation of dendritic cells that leads to the generation of T cells that arecross-talk between the epithelial cells and vulnerable cells shapes and maintains the seditious terrain. The psoriasis isn't a superior complaint like cancer HIV etc. But it have veritably negative impact on patient life due to lack in sense comfort. Research in the many decade helps to medicinal and pharmacological departments to develop and induce the largely effective retailed phrasings in the treatment of psoriasis. In present days, a number of herbal shops are also in the focus of experimenters due to their abundant parcels that will help to control the symptoms of psoriasis. On the other hand, scientists also used the herbal shops to overcome from side goods of topical steroids. For the future, we should have to concentrate on the root cause of this kind of bus-vulnerable complaint as well as rather to treat the symptoms, we should have to do work on the complete treatment of root cause of psoriasis that either be on inheritable position or life style also. Conventional remedy for Psoriasis provides only characteristic relief. There are numerous downsides of conventional remedy and hence, there's a need for the development of new medicine delivery systems which can attack the limitations of conventional product. New phrasings are used to increase the penetration of medicine motes to the target point with reduced side goods. There's a still need for farther disquisition foranti-psoriatic medicines to establish the clinical mileage and artificial scale- up of ways for manufacturing these implicit novel carriers.

REFERENCES

1. Ahmed, A.; Ghourab, M.; Shedid, S.; Qushawy M. Optimization of piroxicamniosomes using central composite design. J. of Phar. Pharmac. Sci., 2013; 5(3): 229-236.
2. Kulkarni, J. S.; Pawar, A. P.; Shedbalkar V. P. Pharmaceutics and Pharmacokinetics, 1sted, CBS Publishers: New Delhi, 2006; 40.

3. Khandare, J. N.; Hemant, J. B.; Ramesh, U. R. Preparation and evaluation of nimesulideniosomes for topical application. Ind. Drug. Bomb, 2001; 38(4): 197-202.
4. Cherukuri, S.; Vuppalapati, L.; Narayanan, V.; Paramanayakam, A.; Balaraman, S. Current trends in treatment and management of psoriasis: an updated review. Int. Res. J. Pharm., 2018; 9(3): 6-16.
5. Guinedi, A. S.; Mortada, N. D.; Mansour, S.; Hathout, R. M. Preparation and evaluation of reverse- phase evaporation and multilamellarniosomes as ophthalmic carriers of acetazolamide. Int. J. Pharm., 2005; 306(1-2): 71-82.
6. Biju, S. S.; Talegaonkar, S.; Mishra, P. R.; Khar, R. K. Vesicular systems: an overview. Ind. J. Pharm. Sci., 2006; 68(2): 141-153.
7. Parnami, N.; Garg, T.; Rath, G.; Goyal, A. K. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Arti. Cel. Nanomed. Biotech, 2014; 42(6): 406-412.
8. Christophers, E. Psoriasis- epidemiology and clinical spectrum. Clin. Eexper. Dermat, 2001; 26(4): 314-320.
9. Henseler, T.; Christophers, E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Ameri. Acad. Dermat, 1985; 13(3): 450-456.
10. Langley, R. G.; Krueger, G. G.; Griffiths, C. E. Psoriasis: epidemiology, clinical features, and quality of life. Annal. Rheum. Dis., 2005; 64(2): 18-23.
11. Garber, K. Anti-IL-17 mAbs herald new options in psoriasis. Nature Biotech, 2012; 30(6): 475- 477.
12. Nickoloff, B. J.; Wrone Smith, T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Amer. J. Patho, 1999; 155(1): 145-158.
13. Ozden, M. G.; Tekin, N.S.; Gürer, M. A.; Akdemir, D.; Doğramac, Ç.; Utaş, S.; Akman, A.; Evans, S. E.; Bahadır, S.; Öztürkcan, S.; İkizoğlu, G. Environmental risk factors in pediatric psoriasis: a multicenter case–control study. Pedia. Dermat, 2011; 28(3): 306- 312.
14. Marripati, S.; Tangri, K.; Reddy, P. J. A review on liposomes. Int. J. Res. Pharm. Nano Sci., 2014; 3(3): 159-169.
15. Witman, P. M. Topical therapies for localized psoriasis. Mayo Clinic Proc., 2001; 76(9): 943-949.
16. Shashi, K.; Rajear, K.; Bharat, P. A complete review on: liposomes. Int. Res. J. Pharm., 2011; 3(7): 10-16.

17. Okare, Zhao D. S.; Luo, Q. Z.; Liu R. H.; Yin, R. Research on surface-modification of Nano- TiO2 by span 60. J. Ceram. Pro. Resour, 2008; 9(4): 398-400.
18. Mahale, N. B.; Thakkar, P. D.; Mali, R. G.; Walunj, D. R.; Chaudhari, S. R. Niosomes: novel sustained release nonionic stable vesicular systems - an overview. Advan. Coll. Inter. Sci., 2012; 183: 46-54.
19. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature, Feb. 22, 2007; 445(7130): 866-73.
20. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. New England Journal of Medicine, Dec. 9, 1999; 341(24): 1817-28.
21. Weigle N, McBaneS. Psoriasis. Am Fam Physician, May., 2013; 87(9): 626–33.
22. P. M. Laws and H. S. Young. Topical treatment of psoriasis. Expert Opinion on Pharmacotherapy, 2010; 11(12): 1999–2009.
23. T. Bhutani, J. Koo, and H. I. Maibach, Efficacy of clobetasol spray: factors beyond patient compliance, Journal of Dermatological Treatment, 2012; 23(1): 11–15.
24. Horn EJ, Domm S, Katz HI, Lebwohl M, Mrowietz U, Kragballe K. Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology and Venereology, Feb. 1, 2010; 24(2): 119-24.
25. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Archives of dermatology, Jan. 1, 1985; 121(1): 63-7.
26. Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: traditional therapy. Annals of the rheumatic diseases, Mar. 1, 2005; 64(2): ii83-6.
27. Menter A, Griffiths CE. Current and future management of psoriasis. The Lancet, Jul. 27, 2007; 370(9583): 272-84.
28. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Jul. 1, 2007; 5(s3): 1-19.
29. Greaves MW, Weinstein GD. Treatment of psoriasis. New England Journal of Medicine, Mar. 2, 1995; 332(9): 581-9.
30. WALTER JF, STOUGHTON RB, DeQUOY PR. Suppression of epidermal proliferation by ultraviolet light, coal tar and anthralin. British Journal of Dermatology, Jul. 1, 1978; 99(1): 89-96.
31. Williams RE, Tillman DM, White SI, Barnett EL, Mackie RM. Re-examining crude coal tar treatment for psoriasis. British Journal of Dermatology, Jun. 1, 1992; 126(6): 608-10.

32. JAN A. Psoriasis: Treatment with calcipotriol. Indian J. Pharm. Sci., 2005; 67(3): 283-91.
33. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev., Jun. 1, 2005; 10(2): 94-111. 2016; 6(11). Khushali Trivedi et al. ISSN NO: 2231-6876
34. Oostveen AM, Beulens CA, Kerkhof PC, Jong EM, Seyger MM. The effectiveness and safety of short-contact dithranol therapy in paediatric psoriasis: a prospective comparison of regular day care and day care with telemedicine. British Journal of Dermatology, Feb 1, 2014; 170(2): 454-7.
35. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, Jorizzo JL, Shmunes E, Tschen EH, Lew-Kaya DA, Lue JC. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. Journal of the American Academy of Dermatology, Jul. 31, 1997; 37(1): 85-92.
36. Martín EG, Sánchez RM, Herrera AE, Umbert MP. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. Journal of drugs in dermatology: JDD, Apr., 2006; 5(4): 334-6.
37. Bandyopadhyay D. Management of Psoriasis: an update. Bulletin on Drug & Health Information. Foundation for Health Action, 2006; 13(2).
38. Huber C, Christophers E. "Keratolytic" effect of salicylic acid. Archives of Dermatological Research, Jan. 1, 1977; 257(3): 293-7.
39. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Advanced drug delivery reviews, Apr. 25, 2001; 47(2): 165-96.
40. Monteiro RiviereNA, editor., Structure and function of skin. Toxicology of the skin. New York: InformaHealthcare USA Inc., 2010; 118.
41. Caubet C, Jonca N, Brattsand M, Guerrin M, Bernard D, Schmidt R, Egelrud T, Simon M, Serre G. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. Journal of Investigative Dermatology, May. 31, 2004; 122(5): 1235-44.
42. Morganti P, Ruocco E, Wolf R, Ruocco V. Percutaneous absorption and delivery systems. Clinics in dermatology, Aug. 31, 2001; 19(4): 489-501.
43. Garg T, K Goyal A. Medicated chewing gum: patient compliance oral drug delivery system. Drug delivery letters, Apr. 1, 2014; 4(1): 72-8.

44. Goyal AK, Rath G, Garg T. Nanotechnological approaches for genetic immunization. InDNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases, 2013; (67 -120). Springer Berlin Heidelberg.
45. Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2014; 31(2).